The HIRA's reimbursed standards for chemotherapy are changed

Changes to groups 1 and 2 were 4 items, 13 treatments were deleted, and 3 items were 12 treatments

The HIRA has changed the chemotherapy benefit standard, four criteria are changed and three criteria are deleted in relation to pancreatic cancer chemotherapy.

 

Changes are made in a total of 25 criteria.

 

The HIRA recently prepared an amendment to 'Details on the Standards and Methods of Applying Medical Care Benefits to Drugs Prescribed and Administered to Cancer Patients.'

As a result, the standard for chemotherapy was improved sequentially, and the standard for chemotherapy related to small cell lung cancer, esophageal cancer, thyroid cancer, hepatobiliary cancer, and head and neck cancer was changed.

 

The chemotherapy for which the reimbursement standard is changed this time is for pancreatic cancer, and the HIRA will conduct an opinion inquiry on the announcement (draft) of the drugs prescribed and administered to cancer patients by the 25th.

 

The effective date is April 1.

 

According to the announcement, the reimbursed standard was changed to 4 items and 13 therapies ▲location of group 1 anticancer drugs (3 therapy) ▲1.

 

Change the phrase of the administration target for the postoperative adjuvant therapy no.1 (1 therapy) ▲2.

 

Palliative therapy a.

 

Administration stage: 'Gemcitabine + Paclitaxel (Albumin-bound)' combination therapy at the first stage 2.

 

Palliative therapy b.

 

Administration stage: Change the administration stage to 1st or more (1 therapy) ▲ 2.

 

Palliative therapy b.

 

At least one of the first steps in the administration phase, changes are made to the target phrases (8 therapy) from 1 to 8 times in a row.

 

The elimination of the reimbursed standard is 3 items and 12 therapies ▲ Classification of group 1 and 2 anticancer drugs and deletion of the table of group 1 anticancer therapy (9 therapy) ▲ 2.

 

Palliative therapy b.

 

Administration stage: at least 1st (3 therapy) ▲2.

 

Palliative therapy b.

 

Dosing step: The first or more week 1 is deleted.

 

The HIRA enacted the anticancer drug reimbursement standard in 2006, allowing clinicians to properly judge and administer Group 1 anticancer drugs within the general principles of approval and anticancer therapy announcements.

 

They were classified as group anticancer drugs and used within the range of the reimbursed standard for each drug.

 

However, opinions have been raised that reclassification of Group 2 anticancer drugs is necessary due to changes in drug prices, registration of generic drugs, and new listing of many high-priced anticancer drugs after the initial enactment.

 

In addition, as clinical evidence is added every year due to the development of new drugs with new mechanisms, the necessity to check old public health therapies has emerged.

 

Accordingly, the HIRA's subcommittee on Cancer Drugs Benefit Appraisal Committee has prepared a reorganization (draft) of reimbursed standards for related fields, and is preparing a new chemotherapy standard by removing the classification of group 1 and group 2 anticancer drugs through the process of collecting opinions from related conferences.